Post Developing Next-Gen Scientific Leaders: The Parker Institute for Cancer Immunotherapy Awards up to $2.9 Million to Eight Early Career Investigators
Post PICI Makes Progress in Toughest Tumor Types with Pancreatic Cancer Combo, Immune Activity in Cold Tumors
Post Parker Institute Researchers Highlighted at CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference #CICON22
Post LumaBridge and the Parker Institute for Cancer Immunotherapy Form Strategic Alliance to Speed Access to Clinical Trial Services for Partners